139508-73-9 Usage
Uses
Used in Pharmaceutical Industry:
Depudecin is used as an HDAC inhibitor for its ability to modulate gene expression and influence cellular processes. It plays a crucial role in the development of therapies targeting various diseases, including cancer.
Used in Cancer Research:
Depudecin is utilized as a research tool in cancer research, specifically for studying the role of HDAC in tumor growth and progression. Its potent inhibition of HDAC enzymes aids in understanding the underlying mechanisms of cancer and the potential for targeted therapies.
Used in Drug Development:
In the drug development sector, Depudecin serves as a lead compound for the creation of novel HDAC inhibitors. Its unique structure and properties make it a promising candidate for the design and synthesis of new drugs with improved efficacy and selectivity.
Used in Anti-angiogenic Applications:
Depudecin is employed as an anti-angiogenic agent, targeting the formation of new blood vessels that supply nutrients to tumors. By inhibiting angiogenesis, Depudecin can potentially limit tumor growth and metastasis, making it a valuable asset in the fight against cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 139508-73-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,9,5,0 and 8 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 139508-73:
(8*1)+(7*3)+(6*9)+(5*5)+(4*0)+(3*8)+(2*7)+(1*3)=149
149 % 10 = 9
So 139508-73-9 is a valid CAS Registry Number.
InChI:InChI=1/C11H16O4/c1-3-7(13)11-9(15-11)5-4-8-10(14-8)6(2)12/h3-13H,1H2,2H3/b5-4+/t6-,7-,8?,9+,10+,11+/m1/s1
139508-73-9Relevant articles and documents
An Olefin Cross-Metathesis Approach to Depudecin and Stereoisomeric Analogues
Cheng-Sánchez, Iván,García-Ruiz, Cristina,Guerrero-Vásquez, Guillermo A.,Sarabia, Francisco
, p. 4744 - 4757 (2017/05/12)
A new total synthesis of the natural product (?)-depudecin, a unique and unexplored histone deacetylase (HDAC) inhibitor, is reported. A key feature of the synthesis is the utilization of an olefin cross-metathesis strategy, which provides for an efficient and improved access to natural depudecin, compared with our previous linear synthesis. Featured by its brevity and convergency, our developed synthetic strategy was applied to the preparation of the 10-epi derivative and the enantiomer of depudecin, which represent interesting stereoisomeric analogues for structure-activity relationship studies.
OCULAR HYPOTENSIVE AGENT COMPRISING COMPOUND CAPABLE OF INHIBITING HISTONE DEACETYLASE AS ACTIVE INGREDIENT
-
, (2009/12/28)
An object of the present invention is to find a novel pharmacological effect of a compound having an HDAC inhibitory effect. The compound having an HDAC inhibitory effect of the invention has an excellent effect of cell morphological change on trabecular meshwork cells and/or effect of intraocular pressure reduction, and is therefore useful as a preventive and/or therapeutic agent for a disease considered to be associated with aqueous humor circulation and/or intraocular pressure, particularly as a preventive and/or therapeutic agent for glaucoma or ocular hypertension.
